Drug intelligence / Profile preview

V940 + pembrolizumab

Development stage: Unknown
Lead developer: Merck
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intramuscular, Intravenous

Overview

This combination involves **V940 (mRNA-4157)**, an individualized neoantigen therapy, and **pembrolizumab (KEYTRUDA)**, an anti-PD-1 checkpoint inhibitor. V940 is designed to induce T-cell responses against specific tumor neoantigens, while pembrolizumab enhances the immune response by blocking the PD-1 pathway. The combination is being investigated for its potential to improve outcomes in patients with resected high-risk melanoma and other cancers by enhancing antitumor immunity.

Brand names: KEYTRUDA
Other names: mRNA-4157/V940 in combination with pembrolizumab

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on V940 + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V940 + pembrolizumab.

Explore the full profile